RNA

Atrium Therapeutics, Inc

• Reuters·07/20 21:58

  ATRIUM THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• TipRanks·07/16 09:45

  Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)

• NASDAQ·07/14 13:17

  Atrium Therapeutics Gains FDA IND Clearance For ATR 1072 In PRKAG2 Syndrome

• TipRanks·07/14 10:40

  Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

• PUBT·07/14 10:40

  Atrium Therapeutics publishes investor presentation on precision RNA medicines for cardiac diseases

• Benzinga·07/14 10:33

  Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 Syndrome

• PUBT·07/14 10:31

  Atrium Therapeutics wins FDA IND clearance for ATR 1072 in PRKAG2 syndrome

• Reuters·07/14 10:30

  ATRIUM THERAPEUTICS - FIRST PARTICIPANT EXPECTED BY END OF 2026; INITIAL DATA ANTICIPATED SECOND HALF 2027

• PR Newswire·07/14 10:30

  Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

• PUBT·06/23 20:05

  Atrium Therapeutics grants 8 new hires stock awards including 66,000 options at $12.66

• PR Newswire·06/23 20:05

  Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

• Dow Jones·06/18 13:00

  Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald

• Dow Jones·06/18 13:00

  Avidity Biosciences Price Target Announced at $25.00/Share by Cantor Fitzgerald

• Benzinga·06/18 12:50

  Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

• TipRanks·06/18 10:12

  Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald